scholarly journals Overexpression ofGPC6andTMEM132Din Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Athanasios Karapetsas ◽  
Antonis Giannakakis ◽  
Denarda Dangaj ◽  
Evripidis Lanitis ◽  
Spyridon Kynigopoulos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
T Lymphocyte ◽  
Early Stage ◽  
Mrna Levels ◽  
Lymphocyte Infiltration ◽  
Ovarian Cancer Cell Lines ◽  
Cd8 T Lymphocyte ◽  
Genes Encoding ◽  
Early Stage Ovarian Cancer

Infiltration of cytotoxic T-lymphocytes in ovarian cancer is a favorable prognostic factor. Employing a differential expression approach, we have recently identified a number of genes associated with CD8+ T-cell infiltration in early stage ovarian tumors. In the present study, we validated by qPCR the expression of two genes encoding the transmembrane proteins GPC6 and TMEM132D in a cohort of early stage ovarian cancer patients. The expression of both genes correlated positively with the mRNA levels ofCD8A, a marker of T-lymphocyte infiltration [Pearson coefficient: 0.427 (p=0.0067) and 0.861 (p<0.0001), resp.].GPC6andTMEM132Dexpression was also documented in a variety of ovarian cancer cell lines. Importantly, Kaplan-Meier survival analysis revealed that high mRNA levels of GPC6 and/or TMEM132D correlated significantly with increased overall survival of early stage ovarian cancer patients(p=0.032). Thus,GPC6andTMEM132Dmay serve as predictors of CD8+ T-lymphocyte infiltration and as favorable prognostic markers in early stage ovarian cancer with important consequences for diagnosis, prognosis, and tumor immunobattling.

scholarly journals Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer

Cancers ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 596 ◽  
Author(s):  
Jing Guo ◽  
Wei-Lei Yang ◽  
Daewoo Pak ◽  
Joseph Celestino ◽  
Karen H. Lu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Late Stage ◽  
Early Stage ◽  
Characteristic Curve ◽  
Stage I ◽  
Inhibitory Factor ◽  
Early Stage Disease ◽  
Biomarker Panel ◽  
Early Stage Ovarian Cancer

Early detection of ovarian cancer promises to reduce mortality. While serum CA125 can detect more than 60% of patients with early stage (I–II) disease, greater sensitivity might be observed with a panel of biomarkers. Ten protein antigens and 12 autoantibody biomarkers were measured in sera from 76 patients with early stage (I–II), 44 patients with late stage (III–IV) ovarian cancer and 200 healthy participants in the normal risk ovarian cancer screening study. A four-biomarker panel (CA125, osteopontin (OPN), macrophage inhibitory factor (MIF), and anti-IL-8 autoantibodies) detected 82% of early stage cancers compared to 65% with CA125 alone. In early stage subjects the area under the receiver operating characteristic curve (AUC) for the panel (0.985) was significantly greater (p < 0.001) than the AUC for CA125 alone (0.885). Assaying an independent validation set of sera from 71 early stage ovarian cancer patients, 45 late stage patients and 131 healthy women, AUC in early stage disease was improved from 0.947 with CA125 alone to 0.974 with the four-biomarker panel (p = 0.015). Consequently, OPN, MIF and IL-8 autoantibodies can be used in combination with CA125 to distinguish ovarian cancer patients from healthy controls with high sensitivity. Osteopontin appears to be a robust biomarker that deserves further evaluation in combination with CA125.

Survival Outcome of Recurrent Early-Stage Ovarian Cancer Patients—What Factors are Important?

2007 ◽  
Vol 107 (2) ◽  
pp. 377-377
Author(s):  
M ZHANG ◽  
C TIAN ◽  
D KAPP ◽  
B MONK ◽  
T HERZOG ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Survival Outcome ◽  
Early Stage Ovarian Cancer

Abstract AS05: Metabolomic signatures in sera from early stage ovarian cancer patients

2015 ◽  
Author(s):  
David A. Gaul ◽  
Christina M. Jones ◽  
Maria Eugenia Monge ◽  
Long Q. Tran ◽  
Martin M. Matzuk ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Early Stage Ovarian Cancer

The Safety and Feasibility of Robotic-Assisted Lymph Node Staging in Early-Stage Ovarian Cancer

2014 ◽  
Vol 24 (8) ◽  
pp. 1493-1498 ◽  
Author(s):  
John V. Brown ◽  
Alberto A. Mendivil ◽  
Lisa N. Abaid ◽  
Mark A. Rettenmaier ◽  
John P. Micha ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Lymph Node Metastases ◽  
Early Stage ◽  
Lymph Node Staging ◽  
Robotic Assisted ◽  
Node Metastases ◽  
The Mean ◽  
Early Stage Ovarian Cancer

ObjectivesThe purpose of this study was to report on the safety and feasibility of robotic-assisted systematic lymph node staging in the management of early-stage ovarian cancer.MethodsWe retrospectively reviewed the charts of presumed early-stage (International Federation of Gynecology and Obstetrics (FIGO) stages I and II) ovarian cancer patients who underwent robotic-assisted surgery that incorporated a systematic pelvic and para-aortic lymphadenectomy from January 2009 until December 2013. Patient demographics, operative characteristics, pathology, lymph node counts, surgical complications, and hospital stay were evaluated.ResultsA total of 26 early-stage ovarian cancer patients were identified. The mean operating time was 2.90 hours, and the estimated blood loss was 63 mL; there were no intraoperative complications although 1 patient’s surgery was significantly prolonged due to pelvic adhesions. The mean number of pelvic and para-aortic lymph nodes removed was 14.6 (2.3% incidence of pelvic lymph node metastases) and 5.8 (3.3% incidence of para-aortic lymph node metastases), respectively. The patients’ mean duration of hospital stay was 18.4 hours, and 2 patients were readmitted for either a postoperative wound infection or vaginal dehiscence.ConclusionsThe results from this study suggest that robotic-assisted surgical staging in the management of presumed early-stage ovarian cancer is both feasible and associated with a minimal patient complication rate. We encountered a low incidence of lymph node metastases, and the readmission rate was favorable. Nevertheless, because the prevalence of lymph node metastases can approach 20% in select patients, physicians should consider a systematic lymph node resection to confer an optimal clinical assessment.

Sign in / Sign up

Export Citation Format

Share Document